Fully Automated HTS Platform for Screening Diverse Targets
High-throughput screening (HTS) remains a foundational technology in early drug discovery, responsible for identifying approximately one-third of today’s clinical candidates. As therapeutic targets become more complex, the demand for HTS platforms that combine high capacity with scientific flexibility continues to grow.
At SLAS 2026, WuXi Biology presented a poster highlighting our fully automated HTS platform, built within a biosafety level 2 (BSL-2) laboratory, enabling safe and efficient processing of immortalized cell lines, primary cells, and clinical samples. The system integrates robotic liquid handling, plate storage/incubation, and multimodal detection, supporting both endpoint and kinetic assays in 384- and 1536-well formats.
Poster_SLAS 2026_Fully Automated HTS Platform
Related Content
High-throughput screening (HTS) remains critical for early drug discovery, yet traditional biochemical assays and specialized techniques such as affinity selection...
VIEW RESOURCEDespite major advances in small molecule drug development, most disease-relevant proteins remain beyond the reach of conventional therapeutics. Molecular glues...
VIEW RESOURCE